[Improvement of survival of testicular cancer patients through chemotherapy].

Naoto Miyanaga, Hideaki Hayashi, Hideyuki Akaza, Kenkichi KoisoPubMed 1995

Abstract

Because treatment of testicular cancer has improved dramatically during the past 15 years, about 70% of the patients can be relieved of this disease today. Although this can be attributed to the availability of various tumor markers, better imaging diagnosis and improvement of surgical techniques, the improvement of chemotherapy, mainly based on cisplatin, has made the largest contribution. Hopefully, more powerful chemotherapy regimens will be available for patients who fail to respond to primary chemotherapy or relapse within a short period after primary chemotherapy. Supportive therapy, such as bone marrow transplantation, will serve to enhance the treatment for testicular cancer. On the other hand, milder therapy will given, if it is determined sufficient to treat the patient with an excellent response to the present therapeutic regimen. In the future, more therapeutic regimens will be prescribed to meet the exact needs of individual patients according to their prognoses.
BibTeX
@inproceedings{miyanaga1995improvement,
  author = {Naoto Miyanaga and Hideaki Hayashi and Hideyuki Akaza and Kenkichi Koiso},
  title = {{[Improvement of survival of testicular cancer patients through chemotherapy].}},
  booktitle = {PubMed},
  year = {1995},
}

Loading related content...

Figure